Retirement Systems of Alabama lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.8% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 452,880 shares of the medical research company’s stock after selling 23,021 shares during the period. Retirement Systems of Alabama’s holdings in Amgen were worth $68,906,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the stock. Raymond James Trust N.A. boosted its position in shares of Amgen by 59.9% in the first quarter. Raymond James Trust N.A. now owns 28,653 shares of the medical research company’s stock worth $4,296,000 after buying an additional 10,739 shares during the last quarter. UMB Bank N A MO boosted its position in shares of Amgen by 6.4% in the first quarter. UMB Bank N A MO now owns 95,896 shares of the medical research company’s stock worth $14,378,000 after buying an additional 5,740 shares during the last quarter. Windward Capital Management Co. CA boosted its position in shares of Amgen by 2.8% in the first quarter. Windward Capital Management Co. CA now owns 27,118 shares of the medical research company’s stock worth $4,066,000 after buying an additional 738 shares during the last quarter. Bridges Investment Management Inc. boosted its position in shares of Amgen by 12.6% in the first quarter. Bridges Investment Management Inc. now owns 22,576 shares of the medical research company’s stock worth $3,466,000 after buying an additional 2,531 shares during the last quarter. Finally, ST Germain D J Co. Inc. boosted its position in shares of Amgen by 1.9% in the first quarter. ST Germain D J Co. Inc. now owns 75,224 shares of the medical research company’s stock worth $11,278,000 after buying an additional 1,376 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.20% during midday trading on Thursday, hitting $166.90. The stock had a trading volume of 1,904,070 shares. The company has a market cap of $124.90 billion, a P/E ratio of 17.08 and a beta of 0.94. The firm has a 50 day moving average of $170.96 and a 200-day moving average of $161.68. Amgen Inc. has a one year low of $139.02 and a one year high of $176.85.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. Amgen’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.57 earnings per share. On average, analysts forecast that Amgen Inc. will post $11.35 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were paid a dividend of $1.00 per share. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 annualized dividend and a yield of 2.40%. Amgen’s dividend payout ratio (DPR) is 40.90%.
Several research firms recently commented on AMGN. Jefferies Group increased their price target on Amgen from $187.00 to $198.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $166.00 price target for the company in a report on Wednesday, June 29th. Citigroup Inc. cut their price target on Amgen from $175.00 to $172.00 and set a “neutral” rating for the company in a report on Wednesday, September 28th. Vetr raised Amgen from a “hold” rating to a “buy” rating and set a $159.50 price target for the company in a report on Monday, June 13th. Finally, Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, June 26th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $184.94.
In related news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.